Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From UnitedHealth Group
Even As PBMs Face Reckoning, Formulary Exclusions Rise Again In 2023
Congressional scrutiny aside, ‘the rebate model remains alive and well’ as the big three pharmacy benefit managers exclude around 600 drugs each from their formularies.
AHIP, PhRMA Try to Control Narrative as Heat on PBMs Intensifies
As health insurance lobby launches advertising campaign to defend ‘evidence-based, market-driven tools,’ drug firms point out the connection between insurers and pharmacy benefit managers.
Stock Watch: Different Regulators Bare Their Teeth At Biotech
When the sector worries about regulation it is usually about drug development and registration. But governments also regulate on monopolistic positions in life sciences. Adding to that, national security enforcement is now rising.
PBM Formulary Exclusions On The Rise, PhRMA Says
According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval.
- Other Names / Subsidiaries
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.